US20060142382A1 - Skin lightening composition - Google Patents

Skin lightening composition Download PDF

Info

Publication number
US20060142382A1
US20060142382A1 US10/540,840 US54084003A US2006142382A1 US 20060142382 A1 US20060142382 A1 US 20060142382A1 US 54084003 A US54084003 A US 54084003A US 2006142382 A1 US2006142382 A1 US 2006142382A1
Authority
US
United States
Prior art keywords
salt
acid
cysteine
derivative
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/540,840
Other languages
English (en)
Inventor
Yoshinobu Morimoto
Asami Watake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32708479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060142382(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Assigned to DAIICHI PHARMACEUTICAL CO., LTD. reassignment DAIICHI PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MORIMOTO, YOSHINOBU, WATAKE, ASAMI
Publication of US20060142382A1 publication Critical patent/US20060142382A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a novel composition, more particularly a composition for whitening (whitening agent).
  • Pigmentations such as chloasmas, freckles, sunburn, dark skin and melanoderma caused by a drug such as steroid are generated by excess deposition of melanin pigment in the skin. It is known that biosynthesis of melanin occurs in a cytoplasmic granule, melanosome, in the melanocyte via a complex pathway in which tyrosine is oxidized by tyrosinase to cause biosynthesis of dopa and dopaquinone, and the dopaquinone is converted into indolequinone or the like due to auto-oxidation by ultraviolet rays. Particularly, such pigmentations are not preferable for women from the beauty point of view.
  • Known preventive and therapeutic agents for pigmentations include L-ascorbic acid and its derivatives (cf. JP-A-49-86554), kojic acid (cf. JP-A-53-3538), L-cysteine (cf. JP-A-59-128320), arbutin (cf. JP-A-60-56912), a bearberry ( Arctostaphylos uva - ursi ) and its extracts (cf. JP-A-6-166609), an admixture of tranexamic acid and ascorbic acid (cf. JP-A-4-243825) and the like.
  • the present invention provides a composition for whitening (whitening agent) having more superior effect.
  • the present invention relates to the followings.
  • Tranexamic acid (trans-4-aminomethylcyclohexanecarboxylic acid) or a salt thereof according to the present invention is a known compound, and regarding its obtaining method, a commercially available product may be used or it may be produced based on a known method.
  • the salt of tranexamic acid include mineral acid salts such as hydrochloride, nitrate, and sulfate; organic acid salts such as methanesulfonate; alkali metal salts or alkaline earth metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and the like. According to the present invention, tranexamic acid is preferred as the tranexamic acid or a salt thereof.
  • the L-cysteine, a derivative thereof or a salt thereof according to the present invention is also a known compound, and as its obtaining method, a commercially available product may be used or it may be produced based on a known method.
  • the derivatives of L-cysteine include N-acetyl-L-cysteine, L-homocysteine, L-cysteic acid, L-homocysteic acid, L-cysteine sulfinic acid, S-sulfino-L-cysteine, S-sulfo-L-cysteine, cystine (dimer of cysteine) and the like.
  • examples of the salt of L-cysteine or a derivative thereof include mineral acid salts such as hydrochloride, nitrate, and sulfate; alkali metal salts or alkaline earth metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and the like.
  • L-cysteine is preferred as the L-cysteine, a derivative thereof or a salt thereof.
  • the L-ascorbic acid, a derivative thereof or a salt thereof according to the present invention is also a known compound, and regarding its obtaining method, a commercially available product may be used or it may be produced based on a known method.
  • the salt of L-ascorbic acid or a derivative thereof include mineral acid salts such as hydrochloride, nitrate, and sulfate; alkali metal salts or alkaline earth metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and the like.
  • L-ascorbic acid examples include L-ascorbic acid; L-ascorbic acid salts such as sodium L-ascorbate, magnesium L-ascorbate, potassium L-ascorbate, and calcium L-ascorbate; ascorbic acid monoalkyl or monoalkenyl esters such as L-ascorbic acid monostearate, L-ascorbic acid monopalmitate, and L-ascorbic acid monooleate; ascorbic acid dialkyl or dialkenyl esters such as L-ascorbic acid distearate, L-ascorbic acid dipalmitate, and L-ascorbic acid dioleate; ascorbic acid trialkyl or trialkenyl esters such as L-ascorbic acid tristearate, L-ascorbic acid tripalmitate, and L-ascorbic acid trioleate; L-ascorbyl sulfates such as L-ascorbic acid; L-ascorbyl
  • composition for whitening (whitening agent) of the present invention is administered to a person aiming at preventing and/or treating pigmentations such as chloasmas, freckles, sunburn, dark skin and melanoderma caused by a drug such as steroid.
  • composition of the present invention may be further blended with known components which show whitening effect and components that reinforce whitening effect.
  • these components include pantothenic acid, derivatives thereof or salts thereof (pantothenic acid; pantothenate, such as sodium pantothenate and calcium pantothenate; pantetheine; pantethine; phosphopantetheine; etc.), hydroquinone or derivatives thereof (hydroquinone; hydroquinone glucoside such as hydroquinone- ⁇ -D-glucose (arbutin); etc.), glucosamine or derivatives thereof (glucosamine; glucosamine esters such as acetylglucosamine; glucosamine ethers such as glucosamine methyl ether; etc.), hinokitiol or derivatives thereof (hinokitiol; hinokitiol glucoside such as hinokitiol glucoside; etc.), azelaic acid, derivatives thereof or salts
  • compositions of the present invention may be blended alone or as a combination of two or more thereof.
  • Components other than the known components which show whitening effect and components that reinforce whitening effect may also be added to the composition for whitening (whitening agent) of the present invention.
  • the blending amounts of these components are not particularly limited, so long as they do not spoil the whitening effect of the composition of the present invention.
  • composition of the present invention may be orally or parenterally administered (dosed).
  • preparations which are orally administered include dosage forms such as tablets, capsules, powders, fine granules, solutions, troches, and jellies.
  • parenteral administration preparations examples include dosage forms such as extracts, hard cream preparations, spirits, suppositories, suspensions, tinctures, ointments, cataplasmas, liniments, lotions, aerosols, ophthalmic solutions, and injections, and dosage forms such as extracts, hard cream preparations, spirits, suspensions, tinctures, ointments, cataplasmas, liniments, lotions, aerosols, ophthalmic solutions, and injections, and dosage forms such as extracts, hard cream preparations, spirits, suspensions, tinctures, ointments, cataplasmas, liniments, lotions, and aerosols are preferred as the parenteral administration preparations.
  • cosmetic compositions such as lotion, cream, face lotion, milky lotion, foam preparations, foundation, pack preparations, skin lotion, shampoo, rinse, and conditioner.
  • Pharmaceuticals can be prepared by conventionally known preparation techniques, and appropriate pharmaceutical additives can be added to the pharmaceuticals.
  • the pharmaceutical additives include excipients, binders, disintegrants, lubricants, glidants, suspending agents, emulsifiers, stabilizers, moisture keeping (moistening) agents, preservatives, solvents, solubilizers, antiseptics, flavoring substances, sweeteners, dyes, flavors, propellants and the like, and these pharmaceutical additives may be selected and added in appropriate amounts within such a range that they do not spoil the effects of the present invention.
  • An appropriate administrating amount (dose) of the composition for whitening of the present invention may be determined by carrying out optional examinations in terms of sex, age and symptoms of each user, administrating (dosing) method, administrating (dosing) frequency, administrating (dosing) time and the like.
  • dose a dose of the composition for whitening of the present invention
  • L-cysteine a derivative thereof or a salt thereof in such a manner that 30 to 750 mg per day of the compound is administered (dosed), and it is more preferable to formulate it in such a manner that 150 to 480 mg of the compound is administered (dosed).
  • L-ascorbic acid, a derivative thereof or a salt thereof in such a manner that 50 to 3,000 mg per day of the compound is administered (dosed), and it is more preferable to formulate it in such a manner that 300 to 2,000 mg of the compound is administered (dosed).
  • composition of the present invention may be administered (dosed) by making it into a single pharmaceutical preparation containing all of the components concerned in the present invention, or each of the components concerned in the present invention may be made into separate pharmaceutical preparations to obtain a kit preparation in which simultaneous or sequential administration (dose) of these preparations is possible.
  • UVB Ultraviolet ray
  • UVB ultraviolet ray
  • Test samples were dissolved in distilled water for injection to the following concentrations.
  • Two guinea pigs in one group were irradiated with an ultraviolet ray (LTVB) for 11 minutes and 30 seconds, and three guinea pigs in one group, from a distance of 40 cm using five SE lamps (wavelength 250 to 350 nm, FL20S ⁇ E, manufactured by TOSHIBA).
  • LTVB ultraviolet ray
  • SE lamps wavelength 250 to 350 nm, FL20S ⁇ E, manufactured by TOSHIBA.
  • each test sample was orally administered twice a day.
  • Each sample solution was administered at a dose of 10 ml/kg. In this case, the administration was carried out after the ultraviolet ray irradiation on each ultraviolet ray irradiation day, or after the judgment on each pigmentation judging day.
  • a ⁇ L value (L value on the observation day—L value before irradiation) was calculated by measuring L value (lightness) of the irradiated site using a color-difference meter (CR-300, manufactured by MINOLTA CAMERA). The results are shown in Table 1 (larger ⁇ L values show higher effect).
  • the samples (6) and (8) concerned in the present invention showed excellent pigmentation inhibitory effect. That is, in comparison with the tranexamic acid-single administered group (sample (2) in the table) and the L-cysteine-single administered group (sample (3) in the table), the tranexamic acid- and L-cysteine-administered group (sample (6) in the table) showed excellent pigmentation inhibitory effect.
  • the L-cysteine- and ascorbic acid-administered group (sample (7) in the table) from which a certain degree of pigmentation inhibitory effect was expected showed no effect contrary to the expectation but rather showed an effect to accelerate pigmentation. This is evident when compared with the results of the L-cysteine-single administered group (sample (3) in the table) and ascorbic acid-single administered group (sample (4) in the table).
  • Tablets were produced in the usual way based on the following composition (6 tablets as daily dose). Tranexamic acid 1,500 mg L-Cysteine 240 mg Microcrystalline cellulose 100 mg Corn starch 40 mg Low substituted hydroxypropylcellulose 50 mg Hydroxypropylcellulose 30 mg Magnesium stearate 20 mg Hydroxypropylmethylcellulose 2910 60 mg Macrogol 6000 12 mg Talc 10 mg Titanium oxide 18 mg 2.2 Tablets
  • Tablets were produced in the usual way based on the following composition (6 tablets as daily dose).
  • Tranexamic acid 750 mg L-Cysteine 240 mg L-Ascorbic acid 300 mg Microcrystalline cellulose 200 mg Corn starch 100 mg Low substituted hydroxypropylcellulose 90 mg Hydroxypropylcellulose 30 mg
  • Tablets were produced in the usual way based on the following composition (6 tablets as daily dose).
  • Tranexamic acid 750 mg L-Cysteine 160 mg L-Ascorbic acid 300 mg ⁇ -Tocopherol 300 mg
  • Tablets were produced in the usual way based on the following composition (6 tablets as daily dose). Tranexamic acid 1,000 mg L-Cysteine 480 mg L-Ascorbic acid 600 mg Pyridoxine hydrochloride 100 mg Riboflavin 30 mg Microcrystalline cellulose 200 mg Corn starch 950 mg Hydroxypropylcellulose 50 mg Magnesium stearate 25 mg Hydroxypropylmethylcellulose 2910 75 mg Macrogol 6000 15 mg Talc 11.5 mg Titanium oxide 22.5 mg 2.5 Solutions
  • Tablets were produced in the usual way based on the following composition (6 tablets as daily dose). Tranexamic acid 1,000 mg L-Cysteine 240 mg Chamomile ( Matricaria chamomilla ) 600 mg Bearberry ( Arctostaphylos uva - ursi ) 300 mg Microcrystalline cellulose 200 mg Corn starch 165 mg Hydroxypropylcellulose 50 mg Magnesium stearate 25 mg Hydroxypropylmethylcellulose 2910 75 mg Macrogol 6000 15 mg Talc 11.5 mg Titanium oxide 22.5 mg 2.7 Tablets
  • Tablets were produced in the usual way based on the following composition (6 tablets as daily dose). Tranexamic acid 1,000 mg L-Cysteine 240 mg Ceramide 20 mg Microcrystalline cellulose 150 mg Corn starch 145 mg Hydroxypropylcellulose 25 mg Magnesium stearate 10 mg Hydroxypropylmethylcellulose 2910 42 mg Macrogol 6000 7 mg Talc 168 mg Titanium oxide 7 mg Sucrose 660 mg Acacia 17 mg Precipitated calcium carbonate 150 mg 2.8 Tablets
  • Tablets were produced in the usual way based on the following composition (6 tablets as daily dose). Tranexamic acid 1,000 mg L-Cysteine 480 mg Flavangenol 30 mg Collagen 1,000 mg Microcrystalline cellulose 203 mg Corn starch 40 mg Low substitution degree hydroxypropylcellulose 70 mg Hydroxypropylcellulose 50 mg Magnesium stearate 27 mg Hydroxypropylmethylcellulose 2910 80 mg Macrogol 6000 16 mg Talc 14 mg Titanium oxide 24 mg 2.9 Vanishing Cream
  • a vanishing cream (100 g) was produced in the usual way based on the following composition.
  • a milky lotion (100 g) was produced in the usual way based on the following composition.
  • a lotion (100 g) was produced in the usual way based on the following composition.
  • composition of the present invention showed excellent melanin pigment deposition inhibitory effect. Accordingly, the composition of the present invention is useful as a composition used for whitening (whitening agent) and also as a composition for the prevention and/or treatment of pigmentations such as chloasmas, freckles, sunburn, dark skin and melanoderma caused by a drug such as steroid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US10/540,840 2002-12-27 2003-12-26 Skin lightening composition Abandoned US20060142382A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002381304 2002-12-27
JP2002381304 2002-12-27
PCT/JP2003/017050 WO2004060364A1 (ja) 2002-12-27 2003-12-26 美白用組成物

Publications (1)

Publication Number Publication Date
US20060142382A1 true US20060142382A1 (en) 2006-06-29

Family

ID=32708479

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/540,840 Abandoned US20060142382A1 (en) 2002-12-27 2003-12-26 Skin lightening composition

Country Status (12)

Country Link
US (1) US20060142382A1 (zh)
EP (1) EP1586315B1 (zh)
JP (1) JP4667875B2 (zh)
KR (3) KR101107754B1 (zh)
CN (1) CN100335048C (zh)
AT (1) ATE464041T1 (zh)
AU (1) AU2003292657A1 (zh)
BR (1) BRPI0317696B8 (zh)
DE (1) DE60332163D1 (zh)
HK (1) HK1084327A1 (zh)
MX (1) MXPA05006924A (zh)
WO (1) WO2004060364A1 (zh)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154577A1 (en) * 2005-12-30 2007-07-05 Industrial Technology Research Institute Herbal compositions inhibiting free radicals
US20080206373A1 (en) * 2007-02-28 2008-08-28 Cheri Lynn Millikin Personal Care Composition Comprising Botanical Extract
US20080241084A1 (en) * 2007-03-29 2008-10-02 Shaklee Corporation Compositions and methods for inhibiting melanogenesis
US20080292689A1 (en) * 2005-12-30 2008-11-27 Lie-Ching Row Method for inhibiting free radicals
US20120282194A1 (en) * 2011-03-28 2012-11-08 Tiffany Florence Topical skin care formulations comprising plant extracts
US20130156710A1 (en) * 2010-05-25 2013-06-20 Symrise Ag Cyclohexyl carbamate compounds as skin and/or hair lightening actives
US8952047B1 (en) 2007-09-18 2015-02-10 Thermolife International, Llc Betaine compounds
US8952045B1 (en) 2007-09-18 2015-02-10 Thermolife International, Llc Amino acid compositions
RU2553352C2 (ru) * 2010-01-12 2015-06-10 Пола Кемикал Индастриз Инк. Агент для профилактики или уменьшения пигментации
KR101670693B1 (ko) * 2009-10-20 2016-10-31 다이이찌 산쿄 헬스케어 가부시키가이샤 변색 및 냄새가 억제된 필름 코팅정
US10292955B2 (en) * 2013-04-04 2019-05-21 Hyundai Pharm Co., Ltd. Composition for external use preparation with improved transdermal permeability
US10426792B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid compositions
US10426750B1 (en) * 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
US10435356B1 (en) * 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
US10646508B1 (en) 2007-09-18 2020-05-12 Thermolife International, Llc Method of safely administering nitrate dietary supplements and compositions
US11534419B2 (en) 2011-04-13 2022-12-27 Thermolife International, Llc N-acetyl beta alanine methods of use
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001342110A (ja) * 2000-06-02 2001-12-11 Ezaki Glico Co Ltd 皮膚外用剤
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090215898A1 (en) 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US8022106B2 (en) 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
JPWO2006003965A1 (ja) * 2004-06-30 2008-04-17 第一三共ヘルスケア株式会社 美白組成物
WO2006023001A1 (en) * 2004-07-30 2006-03-02 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
JP4845363B2 (ja) * 2004-10-01 2011-12-28 ユニチカ株式会社 経口投与組成物及び美白剤
JP5576006B2 (ja) * 2005-01-21 2014-08-20 エスエス製薬株式会社 １日２回服用型経口投与製剤
FI20050453A0 (fi) * 2005-04-29 2005-04-29 Aromtech Ltd Ihonhoitokoostumus
FR2911278B1 (fr) * 2007-01-12 2009-05-01 Limousine D Applic Biolog Dite Procede d'obtention d'un actif cosmetique depigmentant, principe actif obtenu et compositions l'incluant
FR2934158B1 (fr) * 2008-07-23 2012-08-17 Yvon Gauthier Composition dermocosmetique, procede de traitement esthetique a partir de la composition, et utilisation de la composition pour eclaircir la pigmentation de la peau.
TWI477272B (zh) * 2008-08-06 2015-03-21 Daiichi Sankyo Healthcare Co 含有傳明酸及抗壞血酸之安定性醫藥固體製劑組成物
KR101640958B1 (ko) * 2008-09-05 2016-07-19 다이이찌 산쿄 헬스케어 가부시키가이샤 유효 성분이 경계를 사이에 두고 존재하여 이루어지는 의약 고형 제제
US8597683B2 (en) 2010-11-30 2013-12-03 Watson Pharmaceuticals, Inc. Modified release tranexamic acid formulation
CN102698251A (zh) * 2012-06-09 2012-10-03 东莞市照燕生物科技有限公司 一种排毒美白的注射针剂
KR101475609B1 (ko) * 2013-06-12 2014-12-23 중앙대학교 산학협력단 억새꽃 추출물을 유효성분으로 함유하는 피부 미백용 조성물
KR101511252B1 (ko) * 2013-08-06 2015-04-10 주식회사 엘지생활건강 백출추출물과 트라넥삼산을 유효성분으로 포함하는 피부 미백용 조성물
KR101687254B1 (ko) * 2014-06-16 2016-12-16 재단법인 경기과학기술진흥원 피부 미백 효과를 갖는 매듭풀 추출물을 함유하는 화장품 조성물
KR101848887B1 (ko) * 2016-06-29 2018-04-13 에이앤펩주식회사 피부 미백 활성을 가지는 트라넥삼산-펩타이드 및 그 용도
CN106265581B (zh) * 2016-09-30 2020-09-04 上海信谊万象药业股份有限公司 一种氨甲环酸片及其制备方法
KR102042317B1 (ko) * 2017-11-27 2019-11-27 주식회사 씨앤피코스메틱스 피부 미백 및 피부톤 개선 효과가 우수한 화장료 조성물
CN113576933A (zh) * 2021-08-26 2021-11-02 广州环亚化妆品科技有限公司 一种具有美白功效的组合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945094A (en) * 1985-07-09 1990-07-31 Salim Aws S M Synergistic biologically active substances
US5073641A (en) * 1986-08-26 1991-12-17 Hans Bundgaard Prodrug derivatives of carboxylic acid drugs
US20010012853A1 (en) * 1998-03-16 2001-08-09 Bissett Donald Lynn Methods for regulating skin appearance
US20040137077A1 (en) * 2001-02-09 2004-07-15 Margaret Ancira Seborrheic keratosis treatment
US6974833B2 (en) * 2001-01-16 2005-12-13 Matthias Rath Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5543443B2 (zh) 1972-12-25 1980-11-06
JPS533538A (en) 1976-06-28 1978-01-13 Sansho Seiyaku Kk Skin bleach cosmetics
JPS54138130A (en) * 1978-04-14 1979-10-26 Kiguchi Yuugen Cosmetics containing amino acid llcysteine as effective constituent
JPS59128320A (ja) 1983-01-08 1984-07-24 Kanebo Ltd 美白化粧料
JPS6056912A (ja) 1983-09-07 1985-04-02 Shiseido Co Ltd 皮膚外用剤
JPH04243825A (ja) 1991-01-25 1992-08-31 Ss Pharmaceut Co Ltd 色素沈着症治療剤
JP3167148B2 (ja) 1991-09-11 2001-05-21 第一製薬株式会社 美白剤
JPH0680564A (ja) 1992-09-03 1994-03-22 Meiji Seika Kaisha Ltd 抗色素沈着治療薬
JPH1192326A (ja) * 1997-09-22 1999-04-06 Shiseido Co Ltd 皮膚外用剤
KR20010022560A (ko) * 1998-06-05 2001-03-26 겜마 아키라 피부 외용제 조성물
JP2000053529A (ja) * 1998-06-05 2000-02-22 Shiseido Co Ltd 皮膚外用剤
JP4786127B2 (ja) * 2002-07-12 2011-10-05 任康 高田 色素沈着改善治療薬

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945094A (en) * 1985-07-09 1990-07-31 Salim Aws S M Synergistic biologically active substances
US5073641A (en) * 1986-08-26 1991-12-17 Hans Bundgaard Prodrug derivatives of carboxylic acid drugs
US20010012853A1 (en) * 1998-03-16 2001-08-09 Bissett Donald Lynn Methods for regulating skin appearance
US6974833B2 (en) * 2001-01-16 2005-12-13 Matthias Rath Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration
US20040137077A1 (en) * 2001-02-09 2004-07-15 Margaret Ancira Seborrheic keratosis treatment

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980336B2 (en) 2005-12-30 2015-03-17 Industrial Technology Research Institute Method for inhibiting free radicals
US20080292689A1 (en) * 2005-12-30 2008-11-27 Lie-Ching Row Method for inhibiting free radicals
US20070154577A1 (en) * 2005-12-30 2007-07-05 Industrial Technology Research Institute Herbal compositions inhibiting free radicals
US20080206373A1 (en) * 2007-02-28 2008-08-28 Cheri Lynn Millikin Personal Care Composition Comprising Botanical Extract
US9358263B2 (en) * 2007-02-28 2016-06-07 The Procter & Gamble Company Personal care composition comprising botanical extract
US20080241084A1 (en) * 2007-03-29 2008-10-02 Shaklee Corporation Compositions and methods for inhibiting melanogenesis
US10426792B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid compositions
US11155524B2 (en) 2007-09-18 2021-10-26 Thermolife International, Llc Amino acid compositions
US8952045B1 (en) 2007-09-18 2015-02-10 Thermolife International, Llc Amino acid compositions
US8952046B1 (en) 2007-09-18 2015-02-10 Thermolife International, Llc Amino acid compositions
US8957101B1 (en) 2007-09-18 2015-02-17 Thermolife International, Llc Amino acid compositions
US8957100B1 (en) 2007-09-18 2015-02-17 Thermolife International, Llc Amino acid compositions
US11260039B1 (en) 2007-09-18 2022-03-01 Thermolife International, Llc Amino acid compositions
US10555921B1 (en) 2007-09-18 2020-02-11 Thermolife International, Llc Amino acid compositions
US10485777B1 (en) * 2007-09-18 2019-11-26 Thermolife International, Llc Amino acid compositions
US10646508B1 (en) 2007-09-18 2020-05-12 Thermolife International, Llc Method of safely administering nitrate dietary supplements and compositions
US8952047B1 (en) 2007-09-18 2015-02-10 Thermolife International, Llc Betaine compounds
US10472322B1 (en) * 2007-09-18 2019-11-12 Thermolife International, Llc Amino acid supplement formulations
US10894025B1 (en) 2007-09-18 2021-01-19 Thermolife International, Llc Amino acid compositions
US10736916B1 (en) 2007-09-18 2020-08-11 Thermolife International, Llc Methods of improving athletic performance with inorganic nitrate compositions
US10736917B1 (en) 2007-09-18 2020-08-11 Thermolife International, Llc Amino acid compositions
US10426750B1 (en) * 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
US10435356B1 (en) * 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
KR101670693B1 (ko) * 2009-10-20 2016-10-31 다이이찌 산쿄 헬스케어 가부시키가이샤 변색 및 냄새가 억제된 필름 코팅정
US9066914B2 (en) 2010-01-12 2015-06-30 Pola Chemical Industries Inc. Prophylactic or ameliorating agent for pigmentation
RU2553352C2 (ru) * 2010-01-12 2015-06-10 Пола Кемикал Индастриз Инк. Агент для профилактики или уменьшения пигментации
US20130156710A1 (en) * 2010-05-25 2013-06-20 Symrise Ag Cyclohexyl carbamate compounds as skin and/or hair lightening actives
US9072676B2 (en) * 2010-05-25 2015-07-07 Symrise Ag Cyclohexyl carbamate compounds as skin and/or hair lightening actives
US11607380B2 (en) 2011-03-28 2023-03-21 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US11752089B2 (en) 2011-03-28 2023-09-12 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US10328019B2 (en) 2011-03-28 2019-06-25 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US8883224B2 (en) * 2011-03-28 2014-11-11 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US11890369B2 (en) 2011-03-28 2024-02-06 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US11576854B2 (en) 2011-03-28 2023-02-14 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US11833240B2 (en) 2011-03-28 2023-12-05 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US11666525B2 (en) 2011-03-28 2023-06-06 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US11583491B2 (en) 2011-03-28 2023-02-21 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US11684562B2 (en) 2011-03-28 2023-06-27 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US20120282194A1 (en) * 2011-03-28 2012-11-08 Tiffany Florence Topical skin care formulations comprising plant extracts
US11752090B2 (en) 2011-03-28 2023-09-12 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US11534419B2 (en) 2011-04-13 2022-12-27 Thermolife International, Llc N-acetyl beta alanine methods of use
US10292955B2 (en) * 2013-04-04 2019-05-21 Hyundai Pharm Co., Ltd. Composition for external use preparation with improved transdermal permeability
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches

Also Published As

Publication number Publication date
BR0317696A (pt) 2005-11-22
WO2004060364A1 (ja) 2004-07-22
EP1586315A1 (en) 2005-10-19
EP1586315A4 (en) 2008-04-16
MXPA05006924A (es) 2005-12-12
BRPI0317696B8 (pt) 2021-05-25
ATE464041T1 (de) 2010-04-15
KR20080025199A (ko) 2008-03-19
CN1753664A (zh) 2006-03-29
HK1084327A1 (en) 2006-07-28
BRPI0317696B1 (pt) 2016-11-08
EP1586315B1 (en) 2010-04-14
KR101107754B1 (ko) 2012-01-20
DE60332163D1 (de) 2010-05-27
JPWO2004060364A1 (ja) 2006-05-11
KR20080022592A (ko) 2008-03-11
KR20050084492A (ko) 2005-08-26
JP4667875B2 (ja) 2011-04-13
AU2003292657A1 (en) 2004-07-29
CN100335048C (zh) 2007-09-05

Similar Documents

Publication Publication Date Title
EP1586315B1 (en) Skin lightening composition
WO2009067095A1 (en) Topical cosmetic skin lightening compositions and methods of use thereof
US9364424B2 (en) Topical cosmetic skin lightening compositions and methods of use thereof
EP3300731A1 (en) Hair restoration/growth stimulating agent
JP2007519722A (ja) 皮膚の色素沈着を軽減するための全体論的組成物及び方法
KR20130083800A (ko) 피부 주름 개선 및 미백용 조성물
JP6058532B2 (ja) エンドセリン−１産生抑制用組成物、及び細胞増殖促進用組成物
US11166938B2 (en) External composition containing ascorbic acid and/or salts thereof
WO2006003965A1 (ja) 美白組成物
JP2013173730A (ja) 美白用組成物
WO2019230233A1 (ja) デビルズクロー抽出物、それを含有する各種組成物及びデビルズクロー抽出物の製造方法
JP2005314403A (ja) 新規美白用組成物
US20150093345A1 (en) Anti-aging agent containing arctigenin derivative
KR20140017197A (ko) 발아콩 추출물을 포함하는 미백용 또는 탈모 방지용 조성물
JP2004217655A (ja) 美白用組成物
JP5133645B2 (ja) セトラキサートを含有する美白剤
US20070254947A1 (en) Composition for external use
KR20150087141A (ko) 피부 개선용 조성물
KR20080004742A (ko) 디오스게닌을 함유하는 피부미백용 조성물
KR101452061B1 (ko) 아테미신산, 이의 유도체 및 이의 약학적으로 허용 가능한 염을 함유하는 피부 미백제
KR101161738B1 (ko) 진센노사이드 알에이치2를 함유하는 피부미백용 조성물
JP2005194203A (ja) 美白用組成物
KR20160131019A (ko) 식물 제형의 상승작용적 조합을 통한 트리글리세리드 합성의 억제를 위한 조성물 및 방법
KR101155695B1 (ko) 진센노사이드 알지3을 함유하는 피부미백용 조성물
JP2023138179A (ja) Ｍｒｔｆ－ａ遺伝子発現促進剤およびその製造方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: DAIICHI PHARMACEUTICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORIMOTO, YOSHINOBU;WATAKE, ASAMI;REEL/FRAME:017438/0628

Effective date: 20050912

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION